Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286310 | 0.92 | ELANE (0.41) | ELANEKDM4EMAPTLMNAPOLB | |
| SCHEMBL2295072 | 0.78 | ELANE (0.42) | ELANEKDM4EMAPTLMNAPOLB | |
| SCHEMBL15984572 | 0.76 | LMNA (0.49) | ELANEMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL15967677 | 0.76 | ELANE (0.44) | ELANELMNAALDH1A1 | |
| SCHEMBL15984584 | 0.76 | LMNA (0.49) | ELANEMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL15967675 | 0.76 | ELANE (0.44) | ELANELMNAALDH1A1 | |
| SCHEMBL15987256 | 0.75 | ELANE (0.42) | ELANEKDM4EPOLBALDH1A1 | |
| SCHEMBL16003524 | 0.75 | ELANE (0.42) | ELANEMAPTLMNANPSR1 | |
| SCHEMBL16003540 | 0.75 | ELANE (0.42) | ELANEMAPTLMNANPSR1 | |
| SCHEMBL15987201 | 0.75 | ELANE (0.42) | ELANEKDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | ELANE 1960/4885KDM4E 1009/4885MAPT 4368/4885 |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | CPS1, SI, ASNS | ELANE 1609/4885KDM4E 1274/4885MAPT 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.